A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


August 8, 2012

Novel Vaginal HIV Microbicide Ring Enters Large-Scale Clinical Trial

by Tim Horn

AIDS 2012A new clinical trial of a novel drug-infused vaginal microbicide ring to prevent male-to-female transmission of HIV has opened in 17 clinical trials sites in five African countries, according to a National Institutes of Health news announcement and additional details discussed during a press conference at the XIX International AIDS Conference (AIDS 2012) in Washington, DC.

Microbicide Trials Network study 020 (MTN 020)—also known as "A Study to Prevention Infection with a Ring for Extended Use" (ASPIRE)—hopes to enroll nearly 3,500 HIV-negative women at risk for the infection. Results are expected in early 2015.

In July 2010, the CAPRISA 004 clinical trial found that a microbicide gel containing the antiretroviral (ARV) Viread (tenofovir) demonstrated a 39 percent level of efficacy at preventing HIV infection when applied vaginally within 12 hours before and within 12 hours after sex.

In November 2011, however, an interim review of data from another clinical trial—the VOICE study—revealed that the tenofovir gel was no more effective than a placebo gel at preventing HIV infection among females who used the microbicide once daily, regardless of the timing or frequency of sexual acts.

One possible, but unconfirmed, reason for the microbicide’s lackluster results in the VOICE study was poor adherence. Too few women in the trial used the gel as recommended, some experts have suggested.

Enter the ASPIRE study, which will explore a vaginal ring that can give women a discreet, long-acting HIV prevention method they control. This would be particularly helpful in situations where it is difficult or impossible for women to refuse sex, negotiate male condom use with their sexual partners or carefully plan microbicide gel applications.  

The vaginal ring being evaluated in ASPIRE is made of silicone and contains the experimental ARV dapavirine. The drug is continuously released in the vagina and the ring needs to be replaced once every four weeks.

Other vaginal rings in development, according to presenters participating in a scientific session at AIDS 2012, contain the ARVs Invirase (saquinavir), Selzentry (maraviroc) and/or Isentress (raltegravir), with some being combined with hormonal contraceptives.  

The ASPIRE study team, under the direction of Jared Baeten, MD, of the University of Washington in Seattle and Thesla Palanee, PhD, of the Wits Reproductive Health and HIV Institute in Johannesburg, South Africa, will enroll HIV-uninfected women between 18 and 45 years of age in Malawi, South Africa, Uganda, Zambia and Zimbabwe. The participants will be randomly assigned to receive either a silicone ring containing 25 milligrams of dapivirine or a placebo silicone ring. 

During monthly study visits, the women will be tested for HIV and pregnancy and will receive condoms, counseling on how to reduce their risk of becoming infected with HIV and other sexually transmitted infections, and a new silicone ring. Women who become infected with HIV during the study will be told to discontinue using the silicone ring and will be referred to local medical care and support services.

Search: hiv, microbicide, microbicide trials network, mtn, mtn 020, aspire, dapavirine, ring, vaginal, prevention, transmission, women, aids 2012

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (2 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.